TWI316405B - A pharmaceutical composition for reducing pain in a mammal suffering from a neoplasm - Google Patents

A pharmaceutical composition for reducing pain in a mammal suffering from a neoplasm Download PDF

Info

Publication number
TWI316405B
TWI316405B TW092112420A TW92112420A TWI316405B TW I316405 B TWI316405 B TW I316405B TW 092112420 A TW092112420 A TW 092112420A TW 92112420 A TW92112420 A TW 92112420A TW I316405 B TWI316405 B TW I316405B
Authority
TW
Taiwan
Prior art keywords
reovirus
virus
pharmaceutical composition
pain
tumor
Prior art date
Application number
TW092112420A
Other languages
English (en)
Chinese (zh)
Other versions
TW200402305A (en
Inventor
Donald Morris
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of TW200402305A publication Critical patent/TW200402305A/zh
Application granted granted Critical
Publication of TWI316405B publication Critical patent/TWI316405B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW092112420A 2002-05-09 2003-05-07 A pharmaceutical composition for reducing pain in a mammal suffering from a neoplasm TWI316405B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37867502P 2002-05-09 2002-05-09
US44317703P 2003-01-29 2003-01-29

Publications (2)

Publication Number Publication Date
TW200402305A TW200402305A (en) 2004-02-16
TWI316405B true TWI316405B (en) 2009-11-01

Family

ID=29423642

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092112420A TWI316405B (en) 2002-05-09 2003-05-07 A pharmaceutical composition for reducing pain in a mammal suffering from a neoplasm

Country Status (19)

Country Link
US (2) US20040091458A1 (enExample)
EP (1) EP1505992B1 (enExample)
JP (1) JP5241059B2 (enExample)
AR (1) AR039986A1 (enExample)
AT (1) ATE404213T1 (enExample)
AU (1) AU2003229431B8 (enExample)
BR (1) BR0309825A (enExample)
CA (1) CA2484398C (enExample)
DE (2) DE03722131T1 (enExample)
DK (1) DK1505992T3 (enExample)
ES (1) ES2239928T3 (enExample)
IL (1) IL164695A (enExample)
MX (1) MXPA04011007A (enExample)
NZ (1) NZ536102A (enExample)
PT (1) PT1505992E (enExample)
SI (1) SI1505992T1 (enExample)
TR (1) TR200501460T3 (enExample)
TW (1) TWI316405B (enExample)
WO (1) WO2003094938A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
KR20100054358A (ko) * 2008-11-14 2010-05-25 김재은 스틱 연고
AU2010242748B2 (en) * 2009-05-01 2015-07-23 Adare Pharmaceuticals, Inc. Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs
EP2383577A1 (en) * 2010-04-30 2011-11-02 Deutsches Krebsforschungszentrum Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
CA2990133A1 (en) 2015-06-19 2017-03-09 Sillajen, Inc. Compositions and methods for viral embolization
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
NZ518945A (en) * 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus

Also Published As

Publication number Publication date
EP1505992A1 (en) 2005-02-16
NZ536102A (en) 2008-01-31
BR0309825A (pt) 2005-03-01
CA2484398C (en) 2014-01-21
DE03722131T1 (de) 2005-09-15
ATE404213T1 (de) 2008-08-15
AU2003229431B8 (en) 2009-07-02
AU2003229431A1 (en) 2003-11-11
US20040091458A1 (en) 2004-05-13
EP1505992B1 (en) 2008-08-13
JP2005526124A (ja) 2005-09-02
PT1505992E (pt) 2008-10-06
AR039986A1 (es) 2005-03-09
WO2003094938A1 (en) 2003-11-20
DE60322885D1 (de) 2008-09-25
ES2239928T1 (es) 2005-10-16
IL164695A0 (en) 2005-12-18
IL164695A (en) 2010-12-30
SI1505992T1 (sl) 2009-02-28
HK1070565A1 (en) 2005-06-24
TW200402305A (en) 2004-02-16
JP5241059B2 (ja) 2013-07-17
CA2484398A1 (en) 2003-11-20
AU2003229431B2 (en) 2008-01-17
DK1505992T3 (da) 2008-10-06
TR200501460T3 (tr) 2005-06-21
US20080081032A1 (en) 2008-04-03
ES2239928T3 (es) 2009-02-16
MXPA04011007A (es) 2005-02-14

Similar Documents

Publication Publication Date Title
US20080081032A1 (en) Method for reducing pain using oncolytic viruses
Feagan et al. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease
TW200904979A (en) Reoviruses having modified sequences
JP2009525989A (ja) 腫瘍溶解性ウイルスの治療を増強させる局所的免疫抑制の使用
CN104195115A (zh) 突变的呼肠孤病毒及其制备和使用方法
JP2025081671A (ja) オートファジーの誘導のためにチモール及び／又はカルバクロールを使用する組成物及び方法
EP3068411B1 (en) Oncolytic viruses and increased cancer treatment regimens
US20130071432A1 (en) Combination virotherapy for cancer
EP3947685B1 (en) Oligonucleotide-based therapy for ulcerative colitis
CN103055164B (zh) 一种治疗单纯舒张期高血压的中药组合物
CN116637181A (zh) 溶瘤病毒和抗pd-1单抗在协同抑制黑色素瘤中的应用
TW200950777A (en) Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
WO2014172857A1 (zh) 阿可拉定在制备用于治疗原发性肝癌的药物中的用途
EP1944035A1 (en) Method for reducing pain using oncolytic viruses
JP2010077102A (ja) 高齢者向け機能食品および医薬組成物
ZA200408499B (en) Method of reducing pain using oncolytic viruses
CN101378770A (zh) 使用局部免疫抑制改善溶瘤病毒治疗
CN106902121A (zh) 替格瑞洛在过敏性紫癜性肾炎辅助治疗药物中的应用
CN117018075A (zh) 栀子果油的用途
Jennifer Study of Effectiveness of Racecadotril in Acute Watery Diarrhoea in Children Aged Between 3 Months to 5 Years Admitted in Dr. BR Ambedkar Medical College and Hospital
Liebetrau et al. Exposures to liquid detergent capsules in children
CN107582556A (zh) 一种治疗消化性溃疡的药物复方制剂
CN102961559A (zh) 云南白药作为治疗骨癌痛药物的应用
WO2015017915A1 (en) Methods of treating taxane naïve subjects with primary tumors or with metastatic cancer
HK1110512A1 (en) Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent